BBOT Announces New BBO-8520 Data; Focus on 2L+ NSCLC
BBO-8520 plus pembrolizumab showed a 75% ORR in 2L+ KRAS G12C inhibitor-experienced NSCLC. The company highlighted strategic focus on RAS-pathway malignancies and a strong balance sheet of $344.1 million.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day